LHFI – Page 2 – ASCELIA

Skip to content

ASCELIA
AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

En
Sv

About us
- Management
- Board of Directors
Therapeutic areas
- Liver metastases
- Gastric Cancer
Pipeline
- Orviglance®
- Oncoral
Partnering
Investors
Governance
Career
- Open positions
- Our values
Contact

2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Subscribe to press releases

All All press releases Regulatory press releases Financial reports

Regulatory

2019-02-20 | Ascelia Pharma publishes prospectus in connection with Initial Public Offering on Nasdaq Stockholm

Regulatory

2018-05-16 | Ascelia Pharma has raised SEK 60 million to finalize phase III preparations for Mangoral®

Posts navigation

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. […]

Contact

Ascelia Pharma is a Swedish-based specialty oncology drug development company with a late stage pipeline of products. The equity injection of SEK 60 million will be used to advance the development of Ascelia Pharma’s drug candidates – Mangoral® and Oncoral.“I am highly satisfied with the support from both current and new shareholders and their conf ...

Our values

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical […]

Start (en)

About us

Start (en)
About us
Career
Contact
Privacy policy
About cookies
Cookie settings
IMPORTANT INFORMATION

Pipeline

Oncoral
Orviglance^®

IR & Media

Subscribe to press releases
Press releases & News
Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Follow us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance^® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

© Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance.

Video

Cookies

We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy

Settings Accept all

Cookies

Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy

Necessary
These cookies are not optional. They are needed for the website to function.
Statistics
In order for us to improve the website's functionality and structure, based on how the website is used.
Experience
In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
Marketing
By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.

Save Accept all